| 臺大學術典藏 |
2018-09-10T15:02:13Z |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
|
de Azambuja, E. and Holmes, A.P. and Piccart-Gebhart, M. and Holmes, E. and Di Cosimo, S. and Swaby, R.F. and Untch, M. and Jackisch, C. and Lang, I. and Smith, I. and Boyle, F. and Xu, B. and Barrios, C.H. and Perez, E.A. and Azim, H.A. and Kim, S.-B. and Kuemmel, S. and Huang, C.-S. and Vuylsteke, P. and Hsieh, R.-K. and Gorbunova, V. and Eniu, A. and Dreosti, L. and Tavartkiladze, N. and Gelber, R.D. and Eidtmann, H. and Baselga, J.; CHIUN-SHENG HUANG |
